Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.38, $0.03 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $216.8 million versus the consensus estimate of $216.73 million.

"This quarter we saw a return to revenue growth for our hereditary cancer business, an acceleration in our prenatal testing and continued profitability improvements driven by the Elevate 2020 program,” said Mark C. Capone, president and CEO, Myriad Genetics. “Importantly, in the last month, we announced two pivotal events with the publication of the GeneSight GUIDED study and the launch of our expanded Women’s Health sales team, which have the potential to drive transformational growth and long-term shareholder value.”

GUIDANCE:

Myriad Genetics sees Q3 2019 EPS of $0.42-$0.44, versus the consensus of $0.42. Myriad Genetics sees Q3 2019 revenue of $216-218 million, versus the consensus of $215.9 million.

Myriad Genetics sees FY2019 EPS of $1.70-$1.75, versus the consensus of $1.74. Myriad Genetics sees FY2019 revenue of $855-865 million, versus the consensus of $863.69 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.